Oral mucositis continues to be a common and debilitating side effect of the conditioning regimens that use high-dose chemotherapy with or without radiation for pediatric bone marrow transplantation. Limited interventions have demonstrated success in preventing or treating it. Administration of glutamine, which is a nitrogen-rich amino acid found in the body, has emerged as a possible method of preventing oral mucositis in patients undergoing bone marrow transplantation. Numerous studies have looked at the effects of oral glutamine supplementation during bone marrow transplant. The purpose of this article is to describe glutamine and how it functions, review the literature regarding the use of oral glutamine in the prevention of oral mucositis in bone marrow transplantion, discuss the administration concerns related to the pediatric setting, and stress the importance of the nurse's role at the bedside. Nurses working in pediatric bone marrow transplant play a key role in the assessment of oral mucositis, administration of oral glutamine, and education of the patient and family.
Alvarado, Y., Bellm, L. A., & Giles, F. J. (2002). Oral mucositis: Time for more studies. Hematology,7, 281-289.
2.
Anderson, P. M., Ramsay, N. K. C., Shu, X. O., Rydholm, N., Rogosheske, J., Nicklow, R., et al. (1998). Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplantation,22, 339-344.
3.
Anderson, P. M., Schroeder, G., & Skubitz, K. M. (1998). Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer,83, 1433-1439.
4.
Bergstrom, J., Furst, P., Noree, L. O., & Vinnars, E. (1974). Intracellular free amino acid concentration in human muscle tissue. Journal of Applied Physiology,36, 693-697.
5.
Betcher, D., & Baggot, C. (2006). Prevention of mucositis in children with AE0014 a glutamine based oral care regimen for patients diagnosed with solid tumors: A randomized placebo controlled clinical study [PowerPoint presentation]. Available from Children's Oncology Group Web site: www.childrens oncologygroup.org
6.
Blijlevens, N. M., Donnelly, J. P., & De Pauw, B. E. (2000). Mucosal barrier injury: Biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: An overview. Bone Marrow Transplantation,25, 1269-1278.
7.
Cockerham, M. B., Weinberger, B. B., & Lerchie, S. B. (2000). Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. The Annals of Pharmacotherapy,34, 300-303.
8.
Decker, G. M. (2002). Glutamine: Indicated in cancer care?Clinical Journal of Oncology Nursing,6, 112-115.
9.
Dickson, T. M. C., Wong, R. M., Negrin, R. S., Shizuru, J. A., Johnston, L. J., Hu, W. W., et al. (2000). Effect of oral glutamine supplementation during bone marrow transplantation. Journal of Parenteral and Enteral Nutrition,24, 61-66.
10.
Jebb, S. A., Marcus, R., & Elia, M. (1995). A pilot study of oral glutamine supplementation in patients receiving bone marrow transplants. Clinical Nutrition,14, 162-165.
11.
Klimberg, V. S., & McClellan, J. L. (1996). Glutamine, cancer, and its therapy. American Journal of Surgery,172, 418-424.
12.
Lacey, J. M., & Wilmore, D. W. (1990). Is glutamine a conditionally essential amino acid?Nutrition Reviews,48, 297-309.
13.
Miller, A. L. (1999). Therapeutic considerations of l-glutamine: A review of the literature. Alternative Medicine Review,4, 239-248.
14.
Mobrahan, S. (1992). Glutamine: A conditionally essential nutrient or another nutritional puzzle. Nutrition Reviews,50, 331-333.
15.
Muscaritoli, M., Grieco, G., Capria, S., Iori, A. P., & Fanelli, F. R. (2002). Nutritional and metabolic support in patients undergoing bone marrow transplantation. American Journal of Clinical Nutrition,75, 183-190.
16.
Okuno, S. H., Woodhouse, C. O., Loprinzi, C. L., Sloan, J. A., LaVasseur, B. I., Clemens-Schutjer, D., et al. (1999). Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. American Journal of Clinical Oncology,22, 258-261.
17.
Saadeh, C. E. (2005). Chemotherapy and radiotherapy-induced oral mucositis: Review of preventative strategies and treatment. Pharmacotherapy,25, 540-554.
18.
Schloerb, P. R., & Skikne, B. S. (1999). Oral and parenteral glutamine in bone marrow transplantation: A randomized, double-blind study. Journal of Parenteral and Enteral Nutrition,23, 117-122.
19.
Sonis, S. T., Elting, L. S., Keefe, D., Peterson, D. E., Schubert, M., Hauer-Jensen, M., et al. (2004). Perspectives on cancer therapy induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer, 100(Suppl. 9), 1995-2025.
20.
Souba, W. W., Herskowitz, K., Austgen, T. R., Chen, M. K., & Salloum, R. M. (1990). Glutamine nutrition: Theoretical considerations and therapeutic impact. Journal of Parenteral and Enteral Nutrition,14, 237-243.
21.
Souba, W. W., Smith, R. J., & Wilmore, D. W. (1985). Glutamine metabolism by the intestinal tract. Journal of Parenteral and Enteral Nutrition,9, 608-617.
22.
Ward, E., Picton, S., Reid, U., Thomas, D., Gardner, C., Smith, M., et al. (2003). Oral glutamine in paediatric oncology patients: A dose finding study. European Journal of Clinical Nutrition, 57, 31-36.
23.
Wischmeyer, P. E. (2003). Clinical applications of l-glutamine: Past, present, and future. Nutrition in Clinical Practice,18, 377-385.
24.
Yoshida, S., Kaibara, A., Ishibashi, N., & Shirouzu, K. (2001). Glutamine supplementation in cancer patients. Nutrition,17, 766-768.
25.
Ziegler, T. R. (2002). Glutamine supplementation in bone marrow transplantation. British Journal of Nutrition,87(Suppl. 1), 9-15.
26.
Ziegler, T. R.,Young, L. S., Benfell, K., Scheltinga, M., Hortos, K., Bye, R., et al. (1992). Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition following bone marrow transplantation: A randomized, double-blind, controlled study. Annals of Internal Medicine,116, 821-828.
